These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 19654315)

  • 1. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo.
    Yagi N; Manabe I; Tottori T; Ishihara A; Ogata F; Kim JH; Nishimura S; Fujiu K; Oishi Y; Itaka K; Kato Y; Yamauchi M; Nagai R
    Cancer Res; 2009 Aug; 69(16):6531-8. PubMed ID: 19654315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells.
    Amarzguioui M; Peng Q; Wiiger MT; Vasovic V; Babaie E; Holen T; Nesland JM; Prydz H
    Clin Cancer Res; 2006 Jul; 12(13):4055-61. PubMed ID: 16818705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Krüppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1.
    Zheng HQ; Zhou Z; Huang J; Chaudhury L; Dong JT; Chen C
    Oncogene; 2009 Oct; 28(42):3702-13. PubMed ID: 19668233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
    Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
    Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo.
    He XW; Liu T; Chen YX; Cheng DJ; Li XR; Xiao Y; Feng YL
    Cancer Gene Ther; 2008 Mar; 15(3):193-202. PubMed ID: 18202713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice.
    Huh MS; Lee SY; Park S; Lee S; Chung H; Lee S; Choi Y; Oh YK; Park JH; Jeong SY; Choi K; Kim K; Kwon IC
    J Control Release; 2010 Jun; 144(2):134-43. PubMed ID: 20184928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis.
    Komano Y; Yagi N; Onoue I; Kaneko K; Miyasaka N; Nanki T
    J Pharmacol Exp Ther; 2012 Jan; 340(1):109-13. PubMed ID: 21994423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
    Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L
    Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailored design of Au nanoparticle-siRNA carriers utilizing reversible addition-fragmentation chain transfer polymers.
    Kirkland-York S; Zhang Y; Smith AE; York AW; Huang F; McCormick CL
    Biomacromolecules; 2010 Apr; 11(4):1052-9. PubMed ID: 20337403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.
    Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD
    Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
    Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
    Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A non-covalent peptide-based strategy for siRNA delivery.
    Crombez L; Charnet A; Morris MC; Aldrian-Herrada G; Heitz F; Divita G
    Biochem Soc Trans; 2007 Feb; 35(Pt 1):44-6. PubMed ID: 17233597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
    Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
    J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.
    Liu XX; Rocchi P; Qu FQ; Zheng SQ; Liang ZC; Gleave M; Iovanna J; Peng L
    ChemMedChem; 2009 Aug; 4(8):1302-10. PubMed ID: 19533723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome.
    Watanabe T; Umehara T; Yasui F; Nakagawa S; Yano J; Ohgi T; Sonoke S; Satoh K; Inoue K; Yoshiba M; Kohara M
    J Hepatol; 2007 Dec; 47(6):744-50. PubMed ID: 17822798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the development of siRNA-based therapeutics for cancer.
    Shen Y
    IDrugs; 2008 Aug; 11(8):572-8. PubMed ID: 18683092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
    Liu B
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy.
    Kim WJ; Chang CW; Lee M; Kim SW
    J Control Release; 2007 Apr; 118(3):357-63. PubMed ID: 17313987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.